Mphasis stock initiated with Buy rating at UBS on growth recovery potential

UBS initiated coverage on Mphasis Ltd. (MPHL:IN) with a Buy rating and a price target of INR3,370.00, anticipating a significant recovery in revenue growth. The firm projects a 10% compound annual growth rate for Mphasis between fiscal years 2025 and 2028, up from 2% in prior periods, as major headwinds have largely dissipated. UBS believes current valuations do not fully price in this accelerated growth potential, suggesting considerable upside as the company's performance is expected to align with mid-cap peers.

Analysis

UBS has initiated coverage on Mphasis Ltd. (MPHL:IN) with a 'Buy' rating and a price target of INR 3,370.00, signaling a strong conviction in the company's recovery prospects. The core of the thesis is an anticipated acceleration in revenue growth, which UBS believes is not yet reflected in the current valuation. The firm projects a significant increase in Mphasis's compound annual growth rate to 10% for fiscal years 2025-2028, a sharp contrast to the estimated 2% CAGR for fiscal years 2022-2025. This optimism is predicated on the view that major headwinds—including challenges related to its large customer DXC, its subsidiary Digital Risk, and other vertical-specific issues—have now largely subsided. According to UBS's calculations, the current share price implies a long-term revenue CAGR of only 7-8% (FY25-30), whereas their own model supports an 11% CAGR, indicating a clear valuation gap and potential for upside as Mphasis's growth trajectory begins to align with that of its mid-cap peers.

Key Decisions for Investors

• Investors may consider the 'Buy' rating and INR 3,370.00 price target as a strong bullish signal, centered on a potential valuation re-rating if Mphasis achieves the forecasted revenue acceleration.
• The primary factor to monitor is the company's upcoming earnings reports for tangible evidence that headwinds from client DXC have dissipated and that revenue growth is indeed accelerating toward the projected 10% CAGR.
• Given the discrepancy between the market-implied growth of 7-8% and UBS's 11% projection, investors should assess their own long-term growth expectations for Mphasis to determine if they concur with the undervaluation thesis presented.